MASTER PUBLICATION LIST

PUBLICATION LIST 2015 (12)

Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. Paul S, Lindestam Arlehamn CS, Scriba TJ, Dillon MB, Oseroff C, Hinz D, McKinney DM, Carrasco Pro S, Sidney J, Peters B, Sette A. J Immunol Methods. 2015 Apr 7. pii: S0022-1759(15)00098-8. [Epub ahead of print] Impact factor: 2.225 A randomized clinical trial in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette-Guérin (BCG) vaccine administration via a disposable-syringe jet injector to conventional technique with needle and syringe. Geldenhuys HD, Mearns H, Foster J, Saxon E, Kagina B, Saganic L, Jarrahian C, Tameris MD, Dintwe OB, Van Rooyen M, Luabeya KK, Hussey G, Scriba TJ, Hatherill M, Zehrung D. Vaccine. 2015 Apr 7. pii: S0264-410X(15)00393-X. [Epub ahead of print] Impact factor: 3.492 Mycobacterium tuberculosis-specific CD4 T cells are the principal source of IFN-γ in QuantiFERON assays in healthy persons. Penn-Nicholson A, Nemes E, Hanekom WA, Hatherill M, Scriba TJ. Tuberculosis (Edinb). 2015 Mar 10. pii: S1472-9792(14)20623-8. [Epub ahead of print] Impact factor: 3.033 Innovative clinical trial designs to rationalize TB vaccine development. Ellis RD, Hatherill M, Tait D, Snowden M, Churchyard G, Hanekom W, Evans T, Ginsberg AM. Tuberculosis (Edinb). 2015 Mar 6. pii: S1472-9792(14)20661-5. [Epub ahead of print] Impact factor: 3.033 Detection of Mycobacterium tuberculosis DNA on the oral mucosa of tuberculosis patients. Wood RC, Luabeya AK, Weigel KM, Wilbur AK, Jones-Engel L, Hatherill M, Cangelosi GA. Sci Rep. 2015 Mar 2;5:8668. Impact factor: 2.927 A Review and Proposed Approach to the Neutrophilic Dermatoses of Childhood. Webb K, Hlela C, Jordaan HF, Suliman S, Scriba T, Lipsker D, Scott C. Pediatr Dermatol. 2015 Feb 26. [Epub ahead of print] Impact factor: 1.041 Tuberculosis vaccines: time for a global strategy. Kaufmann SH, Evans TG, Hanekom WA. Sci Transl Med. 2015 Feb 25;7(276):276fs8. Impact factor: 10.757 T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Jasenosky LD, Scriba TJ, Hanekom WA, Goldfeld AE. Immunol Rev. 2015 Mar;264(1):74-87. Impact factor: 7.053

MASTER PUBLICATION LIST

The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents. Andrews JR, Hatherill M, Mahomed H, Hanekom WA, Campo M, Hawn TR, Wood R, Scriba TJ. Am J Respir Crit Care Med. 2015 Mar 1;191(5):584-91. Impact factor: 11.041 The impact of HIV exposure and maternal Mycobacterium tuberculosis infection on infant immune responses to bacille Calmette-Guérin vaccination. Jones CE, Hesseling AC, Tena-Coki NG, Scriba TJ, Chegou NN, Kidd M, Wilkinson RJ, Kampmann B. AIDS. 2015 Jan 14;29(2):155-65. Impact Factor: 6.407 Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry. Kagina BM, Mansoor N, Kpamegan EP, Penn-Nicholson A, Nemes E, Smit E, Gelderbloem S, Soares AP, Abel B, Keyser A, Sidibana M, Hughes JE, Kaplan G, Hussey GD, Hanekom WA, Scriba TJ. J Immunol Methods. 2015 Feb;417:22-33. Impact factor: 2.225 Differential leukocyte counting and immunophenotyping in cryopreserved ex vivo whole blood. Nemes E, Kagina BM, Smit E, Africa H, Steyn M, Hanekom WA, Scriba TJ. Cytometry A. 2015 Feb;87(2):157-65. Impact factor: 3.066

PUBLICATION LIST 2014 (24)

Qualification of a Whole Blood Intracellular Cytokine Staining Assay To Measure Mycobacteria-Specific CD4 and CD8 T cell Immunity by Flow Cytometry. Kagina B.M., Mansoor N., Kpamegan E.P., Penn-Nicholson A., Nemes E., Smit E., Gelderbloem S., Soares A.P., Abel B., Keyser A., Sidibana M., Hughes J.E., Kaplan G., Hussey G.D., Hanekom W.A. and Scriba T.J. Journal of Immunological Methods, in press. Impact factor: 2.225 Differential leuckocyte counting and immunophenotyping in cryopreserved ex-vivo whole blood. Nemes E., Kagina B.M.N., Smit E., Africa H., Steyn M., Hanekom W.A. and Scriba T.J. Cytometry Part A, in press. Impact factor: 3.711 Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial. Reither K, Katsoulis L, Beattie T, Gardiner N, Lenz N, Said K, Mfinanga E, Pohl C, Fielding KL, Jeffery H, Kagina BM, Hughes EJ, Scriba TJ, Hanekom WA, Hoff ST, Bang P, Kromann I, Daubenberger C, Andersen P, Churchyard GJ. PLoS One. 2014 Dec 9;9(12):e114602. eCollection 2014. Impact factor: 3.73 Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. Tanner R, Kakalacheva K, Miller E, Pathan AA, Chalk R, Sander CR, Scriba T, Tameris M, Hawkridge T, Mahomed H, Hussey G, Hanekom W, Checkley A, McShane H, Fletcher HA. BMC Infect Dis. 2014 Dec 3;14(1):660. [Epub ahead of print] Impact factor: 3.025 The Combined Use of M. tuberculosis-specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of

MASTER PUBLICATION LIST

Active Tuberculosis. Rozot V, Patrizia A, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, Perreau M, Lazor-Blanchet C, Ohmiti K, Goletti D, Bart PA, Hanekom W, Scriba TJ, Nicod L, Pantaleo G, Harari A. Clin Infect Dis. 2014 Oct 31. Impact factor: 9.374 The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses. Kagina BM, Tameris MD, Geldenhuys H, Hatherill M, Abel B, Hussey GD, Scriba TJ, Mahomed H, Sadoff JC, Hanekom WA; 018-402 Clinical Lab study team; 018-402 Clinical Lab study team. Vaccine. 2014 Sep 9. Impact factor: 3.492 Time to Symptom Resolution in Young Children Treated for Pulmonary Tuberculosis. Mpofu N, Moyo S, Mulenga H, Luabeya KK, Tameris M, Geldenhuys H, Hussey G, Scriba T, Hanekom W, Mahomed H, Hatherill M. Pediatr Infect Dis J. 2014 Aug 20. Impact factor: 3.569 A controlled trial of sputum induction and routine collection methods for TB diagnosis in a South African community. Geldenhuys HD, Whitelaw A, Tameris MD, Van As D, Luabeya KK, Mahomed H, Hussey G, Hanekom WA, Hatherill M. Eur J Clin Microbiol Infect Dis. 2014 Jul 15. Impact factor: 3.024 Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults. Hatherill M, Geldenhuys H, Pienaar B, Suliman S, Chheng P, Debanne SM, Hoft DF, Boom WH, Hanekom WA, Johnson JL. Vaccine. 2014 Jun 30;32(31):3982-8. Impact factor: 3.492 Effect of isoniazid therapy for latent TB infection on QuantiFERON-TB gold in-tube responses in adults with positive tuberculin skin test results in a high TB incidence area: a controlled study. Johnson JL, Geldenhuys H, Thiel BA, Toefy A, Suliman S, Pienaar B, Chheng P, Scriba T, Boom WH, Hanekom W, Hatherill M. Chest. 2014 Mar 1;145(3):612-7. Impact factor: 5.854 Patients with Tuberculosis Disease Have Mycobacterium tuberculosis-Specific CD8 T Cells with a Pro-Apoptotic Phenotype and Impaired Proliferative Capacity, Which Is Not Restored following Treatment. Day CL, Moshi ND, Abrahams DA, van Rooyen M, O'rie T, de Kock M, Hanekom WA. PLoS One. 2014 Apr 16;9(4):e94949. Impact factor: 3.73 Maturation of Innate Responses to Mycobacteria over the First Nine Months of Life. Shey MS, Nemes E, Whatney W, de Kock M, Africa H, Barnard C, van Rooyen M, Stone L, Riou C, Kollmann T, Hawn TR, Scriba TJ, Hanekom WA. J Immunol. 2014 May 15;192(10):4833-43. Impact factor: 5.52 The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. Tameris M, Geldenhuys H, Luabeya AK, Smit E, Hughes JE, Vermaak S, Hanekom WA, Hatherill M, Mahomed H, McShane H, Scriba TJ. PLoS One. 2014 Feb 3;9(2):e87340. Impact factor: 3.73

MASTER PUBLICATION LIST

Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants. Lutwama F, Kagina BM, Wajja A, Waiswa F, Mansoor N, Kirimunda S, Hughes EJ, Kiwanuka N, Joloba ML, Musoke P, Scriba TJ, Mayanja-Kizza H, Day CL, Hanekom WA. J Infect Dis. 2014 Mar;209(6):887-97. Impact factor: 5.848 The impact of HIV exposure and maternal Mycobacterium tuberculosis infection on infant immune responses to bacilli Calmette-Guérin vaccination. Jones CE, Hesseling AC, Tena-Coki NG, Scriba TJ, Chegou NN, Kidd M, Wilkinson RJ, Kampmann B. In press,

AIDS. 2015 Jan 14;29(2):155-65. Impact factor: 6.407 TB Vaccines & Prevention of Infection. Hawn TR, Day TR, Scriba TJ, Hatherill M, Hanekom WA, Evans TG, Churchyard GJ, Kublin JG, Bekker L, Self SG.

Microbiology and Molecular Biology Reviews. 2014 Dec;78(4):650-671. Impact factor: 16.417 High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA; RIFAQUIN Trial Team. N Engl J Med. 2014 Oct 23;371(17):1599-608. Impact factor: 51.658 St John's Wort (Hypericum perforatum L.) photomedicine: hypericin-photodynamic therapy induces metastatic melanoma cell death. Kleemann B, Loos B, Scriba TJ, Lang D, Davids LM. PLoS One. 2014 Jul 30;9(7):e103762. Impact factor: 3.73 Analysis of host responses to Mycobacterium tuberculosis antigens in a multi-site study of subjects with different TB and HIV infection states in sub-Saharan Africa. Sutherland JS, Lalor MK, Black GF, Ambrose LR, Loxton AG, Chegou NN, Kassa D, Mihret A, Howe R, Mayanja-Kizza H, Gomez MP, Donkor S, Franken K, Hanekom W, Klein MR, Parida SK, Boom WH, Thiel BA, Crampin AC, Ota M, Walzl G, Ottenhoff TH, Dockrell HM, Kaufmann SH; GCGH Biomarkers for TB consortium. PLoS One. 2013 Sep 10;8(9):e74080. Impact factor: 3.73 Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response. Matsumiya M, Harris SA, Satti I, Stockdale L, Tanner R, O'Shea MK, Tameris M, Mahomed H, Hatherill M, Scriba TJ, Hanekom WA, McShane H, Fletcher HA. BMC Infect Dis. 2014 Jun 9;14:314. Impact factor: 3.025 Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A. Harris SA, Satti I, Matsumiya M, Stockdale L, Chomka A, Tanner R, O'Shea MK, Manjaly Thomas ZR, Tameris M, Mahomed H, Scriba TJ, Hanekom WA, Fletcher HA, McShane H. Clin Vaccine Immunol. 2014 Jul;21(7):1005-11. Impact factor: 2.598 Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients. Zvada SP, Denti P, Sirgel FA, Chigutsa E, Hatherill M, Charalambous S, Mungofa S, Wiesner L, Simonsson US, Jindani A, Harrison T, McIlleron HM. Antimicrob Agents Chemother. 2014;58(1):503-10.

MASTER PUBLICATION LIST

Impact factor: 4.565 Pediatric intensive care in South Africa: an account of making optimum use of limited resources at the Red Cross War Memorial Children's Hospital*. Argent AC, Ahrens J, Morrow BM, Reynolds LG, Hatherill M, Salie S, Benatar SR. Pediatr Crit Care Med. 2014 Jan;15(1):7-14. Impact factor: 2.354 Differential gene expression of activating Fcγ receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Sutherland JS, Loxton AG, Haks MC, Kassa D, Ambrose L, Lee JS, Ran L, van Baarle D, Maertzdorf J, Howe R, Mayanja-Kizza H, Boom WH, Thiel BA, Crampin AC, Hanekom W, Ota MO, Dockrell H, Walzl G, Kaufmann SH, Ottenhoff TH; GCGH Biomarkers for TB consortium. Clin Microbiol Infect. 2014 Apr;20(4):O230-8. Impact factor: 4.578

PUBLICATION LIST 2013 (15)

Effect of Isoniazid Therapy for Latent Tuberculosis Infection on QuantiFERON-TB Gold In-tube Responses in Tuberculin Skin Test Positive Adults in a High Tuberculosis Incidence Area: A Controlled Study. Johnson JL, Geldenhuys H, Thiel BA, Toefy A, Suliman S, Pienaar B, Chheng P, Scriba T, Boom WH, Hanekom W, Hatherill M. Chest. 2013 Oct Impact factor: 5.854 Knowledge and acceptability of patient-specific infection control measures for pulmonary tuberculosis. Gonzalez-Angulo Y, Geldenhuys H, Van As D, Buckerfield N, Shea J, Mahomed H, Hanekom W, Hatherill M. Am J Infect Control. 2013 Aug;41(8):717-22. Impact factor: 2.731 Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function. Dintwe OB, Day CL, Smit E, Nemes E, Gray C, Tameris M, McShane H, Mahomed H, Hanekom WA, Scriba TJ. Eur J Immunol. 2013 Jul 8. Impact factor: 4.97 Screening for TB in high school adolescents in a high burden setting in South Africa Mahomed H, Ehrlich R, Hawkridge T, Hatherill M, Geiter L, Kafaar F, Abrahams DA, Mulenga H, Tameris M, Geldenhuys H, Hanekom WA, Verver S, Hussey GD. Tuberculosis. 2013 May; 93 (2013) 357-362 Impact factor: 3.033 Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H; the MVA85A 020 Trial Study Team. Lancet. 2013 Mar 23;381(9871):1021-8. Impact factor: 39.06 Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. Tameris M, McShane H, Lmcclain JB, Landry B, Lockhart S, Luabeya AK, Geldenhuys H, Shea J, Hussey G, van der Merwe L, de Kock M, Scriba T, Walker R, Hanekom W, Hatherill M, Mahomed H. Tuberculosis (Edinb). 2013 Mar;93(2):143-9. Impact factor: 3.033 Longitudinal Changes in CD4+ T-Cell Memory Responses Induced by BCG Vaccination of Newborns.

MASTER PUBLICATION LIST

Soares AP, Kwong Chung CK, Choice T, Hughes EJ, Jacobs G, van Rensburg EJ, Khomba G, de Kock M, Lerumo L, Makhethe L, Maneli MH, Pienaar B, Smit E, Tena-Coki NG, van Wyk L, Boom WH, Kaplan G, Scriba TJ, Hanekom WA. J Infect Dis. 2013 Apr;207(7):1084-94. Impact factor: 5.848 Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease. Rozot V, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, Perreau M, Lazor-Blanchet C, Petruccioli E, Hanekom W, Goletti D, Bart PA, Nicod L, Pantaleo G, Harari A. Eur J Immunol. 2013 Jun Impact factor: 4.97 TB incidence in an adolescent cohort in South Africa. Mahomed H, Ehrlich R, Hawkridge T, Hatherill M, Geiter L, Kafaar F, Abrahams DA, Mulenga H, Tameris M, Geldenhuys H, Hanekom WA, Verver S, Hussey GD. PLoS One. 2013;8(3):e59652. Impact factor: 3.73 Induction and Regulation of T Cell Immunity by the Novel TB Vaccine M72/AS01 in South African Adults. Day CL, Tameris M, Mansoor N, van Rooyen M, de Kock M, Geldenhuys H, Erasmus M, Makhethe L, Hughes EJ, Gelderbloem S, Bollaerts A, Bourguignon P, Cohen J, Demoitié MA, Mettens P, Moris P, Sadoff JC, Hawkridge A, Hussey GD, Mahomed H, Ofori-Anyinam O, Hanekom WA. Am J Respir Crit Care Med. 2013 Aug 15;188(4):492-502. Impact factor: 11.041 Vaccine-induced immunity in early life. Kollmann TR, Levy O, Hanekom W. Vaccine. 2013 May Impact factor: 3.492 Varicella Zoster-Specific CD4+Foxp3+ T Cells Accumulate after Cutaneous Antigen Challenge in Humans. Vukmanovic-Stejic M, Sandhu D, Sobande TO, Agius E, Lacy KE, Riddell N, Montez S, Dintwe OB, Scriba TJ, Breuer J, Nikolich-Zugich J, Ogg G, Rustin MH, Akbar AN. J Immunol. 2013 Feb 1;190(3):977-86. Impact factor: Relationship between chemokine receptor expression, chemokine levels and HIV-1 replication in the lungs of persons exposed to Mycobacterium tuberculosis. Kalsdorf B, Skolimowska KH, Scriba TJ, Dawson R, Dheda K, Wood K, Hofmeister J, Hanekom WA, Lange C, Wilkinson RJ. Eur J Immunol. 2013 Feb;43(2):540-9. A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population. McKinney DM, Southwood S, Hinz D, Oseroff C, Arlehamn CS, Schulten V, Taplitz R, Broide D, Hanekom WA, Scriba TJ, Wood R, Alam R, Peters B, Sidney J, Sette A. Immunogenetics. 2013 May;65(5):357-70. Analysis of host responses to Mycobacterium tuberculosis antigens in a multi-site study of subjects with different TB and HIV infection states in sub-Saharan Africa. Sutherland JS, Lalor MK, Black GF, Ambrose LR, Loxton AG, Chegou NN, Kassa D, Mihret A, Howe R, Mayanja-Kizza H, Gomez MP, Donkor S, Franken K, Hanekom W, Klein MR, Parida SK, Boom WH, Thiel BA, Crampin AC, Ota M, Walzl G, Ottenhoff TH, Dockrell HM, Kaufmann SH; GCGH Biomarkers for TB consortium. PLoS One. 2013 Sep

PUBLICATION LIST 2012 (18)

MASTER PUBLICATION LIST

Consensus Statement on Diagnostic End Points for Infant Tuberculosis Vaccine Trials. Hatherill M, Verver S, Mahomed H; the Taskforce on Clinical Research Issues, Stop TB Partnership Working Group on TB Vaccines. Clin Infect Dis. 2012 Feb 15;54(4):493-501. Impact factor: 9.374 Sputum induction for the diagnosis of pulmonary tuberculosis: a systematic review and meta-analysis. Gonzalez-Angulo Y, Wiysonge CS, Geldenhuys H, Hanekom W, Mahomed H, Hussey G, Hatherill M. Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1619-30. Impact factor: 3.024 Diagnostic Features Associated With Culture of Mycobacterium tuberculosis Among Young Children in a Vaccine Trial Setting. Luabeya KK, Mulenga H, Moyo S, Tameris M, Sikhondze W, Geldenhuys H, Mohamed H, Hanekom W, Hussey G, Hatherill M. Pediatr Infect Dis J. 2012 Jan 31(1):42-6. PMID: 22094639. Impact factor: 3.569 Safety and tolerability of sputum induction in adolescents and adults with suspected pulmonary tuberculosis. Geldenhuys HD, Kleynhans W, Buckerfield N, Tameris M, Gonzalez Y, Mahomed H, Hussey G, Hanekom W, Hatherill M. Eur J Clin Microbiol Infect Dis. 2012 Apr;31(4):529-37. Impact factor: 3.024 Optimization of a whole blood intracellular cytokine assay for measuring innate cell responses to mycobacteria. Shey MS, Hughes EJ, de Kock M, Barnard C, Stone L, Kollmann TR, Hanekom WA, Scriba TJ. J Immunol Methods. 2012 Feb 28;376(1-2):79-88. Impact factor: 2.225 A phase IIa Trial of the new TB Vaccine, MVA85A, in HIV and/or M. Tuberculosis Infected Adults. Scriba TJ, Tameris M, Smit E, van der Merwe L, Hughes EJ, Kadira B, Mauff K, Moyo S, Brittain N, Lawrie A, Mulenga H, de Kock M, Makhethe L, van Rensburg EJ, Gelderbloem S, Veldsman A, Hatherill M, Geldenhuys H, Hill AV, Hawkridge A, Hussey GD, Hanekom WA, McShane H, Mahomed H. Am J Respir Crit Care Med. 2012 Jan 26. Impact factor: 2.731 SATVI - after 10 years closing in on a new and better vaccine to prevent tuberculosis. Hanekom WA, Hawkridge A, Mahomed H, Scriba TJ, Tameris M, Hughes J, Hatherill M, Day CL, Hussey GD. S Afr Med J. 2012;102(6):438-41. Impact factor: 1.702 Vaccine trials in the developing world: operational lessons learnt from a phase IV poliomyelitis vaccine trial in South Africa. Geldenhuys H, Waggie Z, Jacks M, Geldenhuys M, Traut L, Tameris M, Hatherill M, Hanekom WA, Sutter R, Hussey G, Mahomed H. Vaccine. 2012;30(40):5839-43. Impact factor: 3.492 Predictive Value of Recent QuantiFERON Conversion for Tuberculosis Disease in Adolescents. Machingaidze S, Verver S, Mulenga H, Abrahams DA, Hatherill M, Hanekom W, Hussey GD, Mahomed H. Am J Respir Crit Care Med. 2012;186(10):1051-6. Impact factor: 11.041 The Influence of Bacille Calmette-Guerin Vaccine Strain on the Immune Response against Tuberculosis: A Randomized Trial. Ritz N, Dutta B, Donath S, Casalaz D, Connell TG, Tebruegge M, Robins-Browne R, Hanekom WA, Britton WJ, Curtis N. Am J Respir Crit Care Med. 2012 Jan 15;185(2):213-22. Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cells.

MASTER PUBLICATION LIST

Walker LJ, Kang YH, Smith MO, Tharmalingham H, Ramamurthy N, Fleming VM, Sahgal N, Leslie A, Oo Y, Geremia A, Scriba TJ, Hanekom WA, Lauer GM, Lantz O, Adams DH, Powrie F, Barnes E, Klenerman P. Blood. 2012 Jan 12;119(2):422-33. HIV-1 infection alters CD4+ memory T-cell phenotype at the site of disease in extrapulmonary tuberculosis. Matthews K, Ntsekhe M, Syed F, Scriba T, Russell J, Tibazarwa K, Deffur A, Hanekom W, Mayosi BM, Wilkinson RJ, Wilkinson KA.Eur J Immunol. 2012 Jan;42(1):147-57. PMID: 22215422 Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine. Zvada SP, Denti P, Geldenhuys H, Meredith S, van As D, Hatherill M, Hanekom W, Wiesner L, Simonsson US, Jindani A, Harrison T, McIlleron HM. Antimicrob Agents Chemother. 2012 Aug;56(8):4471-3. Meeting report: The International Conference on Human Immunity to Tuberculosis. Ernst JD, Hanekom W, Hawn T, Kampmann B, Rengarajan J. Tuberculosis (Edinb). 2012;92(5):440-4. Key issues in the clinical development and implementation of TB vaccines in South Africa. Rustomjee R, Mcleod R, Hanekom W, Steel G, Mahomed H, Hawkridge A, Welte A, Sinanovic E, Loots G, Grobler A, Mvusi L, Gray G, Hesseling A, Ginsberg A, Lienhardt C, Shea J, Tong X, Lockhart S, Churchyard GJ. Tuberculosis (Edinb). 2012;92(5):359-64. Detection and treatment of subclinical tuberculosis. Robertson BD, Altmann D, Barry C, Bishai B, Cole S, Thomas Dick, Duncan K, Dye C, Ehrt S, Esmail H, Flynn J, Hafner R, Handley G, Hanekom W, van Helden P, Kaplan G, Kaufmann SH, Kim P, Lienhardt C, Mizrahi V, Rubin E, Schnappinger D, Sherman D, Thole J, Vandal O, Walzl G, Warner D, Wilkinson R, Young D. Tuberculosis (Edinb). 2012;92(6):447-52. A comparative analysis of polyfunctional T cells and secreted cytokines induced by Bacille Calmette-Guérin immunisation in children and adults. Ritz N, Strach M, Yau C, Dutta B, Tebruegge M, Connell TG, Hanekom WA, Britton WJ, Robins-Browne R, Curtis N. PLoS One. 2012;7(7):e37535. Genetic Variation in TLR Genes in Ugandan and South African Populations and Comparison with HapMap Data. Baker AR, Qiu F, Randhawa AK, Horne DJ, Adams MD, Shey M, Barnholtz-Sloan J, Mayanja-Kizza H, Kaplan G, Hanekom WA, Boom WH, Hawn TR, Stein CM; Tuberculosis Research Unit (TBRU) and South African Tuberculosis Vaccine Initiative Team (SATVI). PLoS One. 2012;7(10):e47597.

PUBLICATION LIST 2011 (21)

Prospects for elimination of childhood tuberculosis: the role of new vaccines. Hatherill M. Arch Dis Child. 2011 Sep;96(9):851-6. Impact factor: 3.051 Safety and tolerability of sputum induction in adolescents and adults with suspected pulmonary tuberculosis. Geldenhuys HD, Kleynhans W, Buckerfield N, Tameris M, Gonzalez Y, Mahomed H, Hussey G, Hanekom W, Hatherill M. Eur J Clin Microbiol Infect Dis. 2012 Apr;31(4):529-37 Impact factor: 3.024 Phenotypic variability in childhood TB: Implications of diagnostic endpoints in tuberculosis vaccine trials. Mulenga H, Moyo S, Workman L, Hawkridge T, Verver S, Tameris M, Geldenhuys H, Hanekom W, Mahomed H, Hussey G, Hatherill M. Journal of Vaccine 2011. Jun 10;29(26):4316-2 Impact factor: 3.492 Dose-Finding Study of the Novel Tuberculosis Vaccine, MVA85A, in Healthy BCG-Vaccinated Infants.

MASTER PUBLICATION LIST

Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Mauff K, Hughes EJ, Moyo S, Brittain N, Lawrie A, Mulenga H, de Kock M, Gelderbloem S, Veldsman A, Hatherill M, Geldenhuys H, Hill AV, Hussey GD, Mahomed H, Hanekom WA, McShane H. J Infect Dis. 2011;203(12):1832-43. Impact factor: 5.848 Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosis. Matthews K, Wilkinson KA, Kalsdorf B, Roberts T, Diacon A, Walzl G, Wolske J, Ntsekhe M, Syed F, Russell J, Mayosi BM, Dawson R, Dheda K, Wilkinson RJ, Hanekom WA and Scriba TJ. Journal of Tuberculosis 2011 Nov;91(6):587-93. Impact factor: 3.033 Prospects for a new, safer and more effective TB vaccine. Hawkridge T, Mahomed H. Paediatr Respir Rev. 2011 Mar;12(1):46-51. Impact factor: 2.792 Tuberculin skin test and QuantiFERON assay in young children investigated for tuberculosis in South Africa. Moyo S, Isaacs F, Gelderbloem S, Verver S, Hawkridge AJ, Hatherill M, Tameris M, Geldenhuy H, Workman L, Pai M, Hussey G, Hanekom WA, Mahomed H. Int J Tuberc Lung Dis 2011 Sep;15(9):1176-81. Impact factor: 2.61 Risky Behaviour and Psychosocial Correlates in Adolescents – is there a link with Tuberculosis? Geldenhuys H, Sorsdahl K, Kafaar F, Hatherill M, Hanekom WA, Stein DJ, Mahomed H. Afric J Psychiatry 2011 Nov;14(5):383-7. doi: Impact factor: 2.575 Functional Capacity of Mycobacterium tuberculosis-Specific T Cell Responses in Humans Is Associated with Mycobacterial Load Cheryl L. Day, Deborah A. Abrahams, Lesedi Lerumo, Esme Janse van Rensburg, Lynnett Stone, Terrence O’rie, Bernadette Pienaar, Marwou de Kock, Gilla Kaplan, Hassan Mahomed, Keertan Dheda, and Willem A. Hanekom. J Immunol. 2011 Sep 1;187(5):2222-32 Impact factor: 5.52 HIV specific gag responses in early infancy correlate with clinical outcome and inversely with viral load Nqoko B, Day C, Mansoor N, de Kock M, Hughes EJ, Hawkdridge T, Kaplan G, Boom WH, Hussey GD, Hanekom WA. AIDS Res Hum Retroviruses. 2011 Dec;27(12):1311-6. Impact factor: 2.705 Predictive factors for latent tuberculosis infection among adolescents in a high burden area in South Africa. Hassan Mahomed, Tony Hawkridge, Suzanne Verver, Lawrence Geiter, Mark Hatherill, Deborah-Ann Abrahams, Rodney Ehrlich, Willem Albert Hanekom, Gregory Dudley Hussey on behalf of the SATVI adolescent study team. Int J Tuberc Lung Dis 2011 Mar;15(3):331-6. Impact factor: 5.848 Developing vaccinology expertise for Africa: six years and counting. Wiysonge CS, Waggie Z, Mahomed H, Hawkridge A, Hatherill M, Hanekom W, Hussey GD. Vaccine 2011. Aug 11;29(35):5821-3. Impact factor: 3.492 The tuberculin skin test versus Quantiferon TB Gold in predicting tuberculosis disease in an adolescent cohort study in South Africa. Mahomed H, Hawkridge T, Verver S, Abrahams D, Geiter L, Hatherill M, Ehrlich R, Hanekom WA, Hussey GD. PLoS One. 2011 Mar 29;6(3):e17984. Impact factor: 3.492 The Utility of an Interferon Gamma Release Assay for Diagnosis of Latent Tuberculosis Infection and Disease in Children: A Systematic Review and Meta-analysis.

MASTER PUBLICATION LIST

Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y, Hatherill M, Moyo S, Hanekom W, Mahomed H. Pediatr Infect Dis J. 2011 Aug;30(8):694-700. Impact factor: 3.569 Dominant TNF-α (+) Mycobacterium tuberculosis-specific CD4(+) T cell responses discriminate between latent infection and active disease. Harari A, Rozot V, Enders FB, Perreau M, Stalder JM, Nicod LP, Cavassini M, Calandra T, Blanchet CL, Jaton K, Faouzi M, Day CL, Hanekom WA, Bart PA, Pantaleo G. Nat Med. 2011 Mar;17(3):372-6. Impact factor: 22.864 Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa. Mahomed H, Hawkridge T, Verver S, Geiter L, Hatherill M, Abrahams DA, Ehrlich R, Hanekom WA, Hussey GD; SATVI Adolescent Study Team. Int J Tuberc Lung Dis. 2011 Mar; 15(3):331-6. Impact factor: 2.61 Identification of antigens specific to non-tuberculous mycobacteria: the Mce family of proteins as a target of T cell immune responses. Checkley AM, Wyllie DH, Scriba TJ, Golubchik T, Hill AV, Hanekom WA, McShane H. PLoS One. 2011;6(10):e26434. Immune activation in the female genital tract during HIV infection predicts mucosal CD4 depletion and HIV shedding. Jaspan HB, Liebenberg L, Hanekom W, Burgers W, Coetzee D, Williamson AL, Little F, Myer L, Coombs RW, Sodora D, Passmore JA. J Infect Dis. 2011 Nov 15;204(10):1550-6 Association of Human TLR1 & TLR6 Deficiency with Altered Immune Responses to BCG Vaccination in South African Infants. Randhawa AK, Shey M, Keyser A, Peixoto B, Wells R, de Kock M, Lerumo L, Hughes J, Hussey G, Hawkridge A, Kaplan G, Hanekom W, Hawn T. Plos Pathog 2011 August; 7(8): e1002174. Immunological biomakers in Tuberculosis. Walzl G, Ronacher K, Hanekom W, Scriba T, Zumla A. Nature Rev Immunol. 2011 April 08. May;11 (5) :343-54 Induction of granulysin and perforin cytolytic mediator expression in 10-week-old infants vaccinated with BCG at birth. Semple PL, Watkins M, Davids V, Krensky AM, Hanekom WA, Kaplan G, Ress S. Clin Dev Immunol. 2011; 2011:438463.

PUBLICATION LIST 2010 (15)

Novel vaccine prime and selective BCG boost: a new tuberculosis vaccine strategy for infants of HIV-infected mothers. Hatherill M, Mahomed H, Hanekom W. Vaccine. 2010 Jun 23; 28(29):4550-2. Impact factor: 3.492 Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Isaacs F, Keyser A, Moyo S, Brittain N, Lawrie A, Gelderbloem S, Veldsman A, Hatherill M, Hawkridge A, Hill AV, Hussey GD, Mahomed H, McShane H, Hanekom WA. Eur J Immunol. 2010;40(1) Impact factor: 4.97 Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. Govender L, Abel B, Hughes EJ, Scriba TJ, Kagina BM, de Kock M, Walzl G, Black G, Rosenkrands I, Hussey GD, Mahomed H, Andersen P, Hanekom WA. Vaccine. 2010 Dec 10; 29(1):51-7.

MASTER PUBLICATION LIST

Impact factor: 3.492 Specific T Cell Frequency and Cytokine Expression Profile do not correlate withprotection against tuberculosis, following BCG vaccination of newborns. Kagina BM, Abel B, Scriba TJ, Hughes EJ, Keyser A, Soares A, Gamieldien H, Sidibana M, Hatherill M, Gelderbloem S, Mahomed H, Hawkridge A, Hussey G, Kaplan G, Hanekom WA; other members of SATVI. Am J Respir Crit Care Med. 2010 Oct 15;182(8):1073-9. Impact factor: 11.041 The Tuberculin Skin Test: a comparison of reading with a ruler to reading with a calliper. Hennie Geldenhuys, Suzanne Verver, Shireen Surtie, Mark Hatherill, Frank van Leth, Fazlin Kafaar, Michele Tameris, William Kleynhans, Kany Kany Luabeya, Sizulu Moyo, Welile Sikhondze, Willem Hanekom, Hassan Mahomed Int J Tuberc Lung Dis 2010. Impact factor: 2.61 Age-related tuberculosis incidence and severity in children under 5 years of age in Cape Town, South Africa. Moyo S, Verver S, Mahomed H, Hawkridge A, Kibel M, Hatherill M, Tameris M, Geldenhuys H, Hanekom W, Hussey G. Int J Tuberc Lung Dis. 2010 Feb;14(2):149-54. Impact factor: 2.61 CD4 and CD8 T Cell Responses to Mycobacterial Antigens in African Children. Tena-Coki NG, Scriba TJ, Peteni N, Eley B, Wilkinson RJ, Andersen P, Hanekom WA, Kampmann B. Am J Respir Crit Care Med. 2010. Impact factor: 11.041 The Novel TB Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4 and CD8 T Cells in Adults. Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, Abrahams D, Makhethe L, Erasmus M, de Kock M, van der Merwe L, Hawkridge A, Veldsman A, Hatherill M, Schirru G, Pau MG, Hendriks J, Weverling GJ, Goudsmit J, Sizemore D, McClain JB, Goetz M, Gearhart J, Mahomed H, Hussey GD, Sadoff JC, Hanekom WA. Am J Respir Crit Care Med. 2010. Impact factor: 11.041 Tuberculosis research update. Hanekom WA, Lawn SD, Dheda K, Whitelaw A. Trop Med Int Health. 2010 Aug; 15(8):981-9. Impact factor: 2.938 Single nucleotide polymorphisms in toll-like receptor 6 are associated with altered lipopeptide- and mycobacteria-induced interleukin-6 secretion. Shey MS, Randhawa AK, Bowmaker M, Smith E, Scriba TJ, de Kock M, Mahomed H, Hussey G, Hawn TR, Hanekom WA. Genes Immun. 2010 Oct; 11(7):561-72. Impact factor: 3.675 Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. Joosten SA, van Meijgaarden KE, van Weeren PC, Kazi F, Geluk A, Savage ND, Drijfhout JW, Flower DR, Hanekom WA, Klein MR, Ottenhoff TH. PLoS Pathog. 2010;6(2) High heritability of antimycobacterial immunity in an area of hyperendemicity for tuberculosis disease. Cobat A, Gallant CJ, Simkin L, Black GF, Stanley K, Hughes J, Doherty TM, Hanekom WA, Eley B, Beyers N, Jaïs JP, van Helden P, Abel L, Hoal EG, Alcaïs A, Schurr E. J Infect Dis. 2010;201(1):15-9. Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation. Soares A, Govender L, Hughes J, Mavakla W, de Kock M, Barnard C, Pienaar B, Janse van Rensburg E, Jacobs G, Khomba G, Stone L, Abel B, Scriba TJ, Hanekom WA. J Immunol Methods. 2010 Oct 31; 362(1-2):43-50. Impact of age and sex on mycobacterial immunity in an area of high tuberculosis incidence. Gallant CJ, Cobat A, Simkin L, Black GF, Stanley K, Hughes J, Doherty TM, Hanekom WA, Eley B, Beyers N, Jaïs JP, van Helden P, Abel L, Alcaïs A, Hoal EG, Schurr E. Int J Tuberc Lung Dis. 2010 Aug;14(8):952-9.

MASTER PUBLICATION LIST

Comparison of polyclonal expansion methods to improve the recovery of cervical cytobrush-derived T cells from the female genital tract of HIV-infected women. Bere A, Denny L, Hanekom W, Burgers WA, Passmore JA. J Immunol Methods. 2010 Mar 31; 354(1-2):68-79. Tuberculin skin test and in-vitro assays provide complementary measures of anti-mycobacterial immunity in children and adolescents. Gallant CJ, Cobat A, Simkin L, Black GF, Stanley K, Hughes J, Doherty TM, Hanekom WA, Eley B, Beyers N, Jaïs JP, van Helden P, Abel L, Alcaïs A, Hoal EG, Schurr E. 2010 May;137(5):1071-7.

PUBLICATION LIST 2009 (15)

Structured approaches for the screening and diagnosis of childhood tuberculosis in a high prevalence region of South Africa. Hatherill M, Hanslo M, Hawkridge T, Little F, Workman L, Mahomed H, Michele Tameris, Sizulu Moyo, Hennie Geldenhuys, Willem Hanekom, Lawrence Geiter, Gregory Hussey. Bull World Health Organ 2009;88:312-320. Impact factor: 5.25 The potential impact of helminth infection on trials of novel tuberculosis vaccines. Hatherill M, Adams V, Hughes J, De Kock M, Mavakla W, Pienaar B, Mahomed H, Hussey G, Hanekom WA. Vaccine. 2009;27(35):4743-4. Impact factor: 3.492 Induced sputum or gastric lavage for community-based diagnosis of childhood pulmonary tuberculosis? Hatherill M, Hawkridge T, Zar HJ, Whitelaw A, Tameris M, Workman L, Geiter L, Hanekom WA, Hussey G. Arch Dis Child. 2009;94(3):195-201. Impact factor: 3.051 Comparison of Mantoux and Tine tuberculin skin tests in BCG-vaccinated children investigated for tuberculosis. Pan W, Matizirofa L, Workman L, Hawkridge T, Hanekom W, Mahomed H, Hussey G, Hatherill M. PLoS ONE 2009;4:e8085. Doi:10.1371/journal.pone.0008085. Impact factor: 3.73 Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. Kagina BM, Abel B, Bowmaker M, Scriba TJ, Gelderbloem S, Smit E, Erasmus M, Nene N, Walzl G, Black G, Hussey GD, Hesseling AC, Hanekom WA. Vaccine. 2009;27(40):5488-95. Impact factor: 3.492 HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine. Mansoor N, Scriba TJ, de Kock M, Tameris M, Abel B, Keyser A, Little F, Soares A, Gelderbloem S, Mlenjeni S, Denation L, Hawkridge A, Boom WH, Kaplan G, Hussey GD, Hanekom WA. J Infect Dis. 2009;199(7):982-90. 15. Impact factor: 5.848 Significantly skewed memory CD8+ T cell subsets in HIV-1 infected infants during the first year of life. Mansoor N, Abel B, Scriba TJ, Hughes J, de Kock M, Tameris M, Mlenjeni S, Denation L, Little F, Gelderbloem S, Hawkridge A, Boom WH, Kaplan G, Hussey GD, Hanekom WA. Clin Immunol. 2009;130(3):280-9. Impact factor: 3.771 New vaccines against tuberculosis. Lambert PH, Hawkridge T, Hanekom WA. Clin Chest Med. 2009;30(4):811-26. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. Cobat A, Gallant CJ, Simkin L, Black GF, Stanley K, Hughes J, Doherty TM, Hanekom WA, Eley B, Jaïs JP, Boland-Auge A, van Helden P, Casanova JL, Abel L, Hoal EG, Schurr E, Alcaïs A. J Exp Med. 2009;206(12):2583-9.

MASTER PUBLICATION LIST

HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Kalsdorf B, Scriba TJ, Wood K, Day CL, Dheda K, Dawson R, Hanekom WA, Lange C, Wilkinson RJ. Am J Respir Crit Care Med. 2009;180(12):1262-70. Impact of human immunodeficiency virus 1 infection and inflammation on the composition and yield of cervical mononuclear cells in the female genital tract. Nkwanyana NN, Gumbi PP, Roberts L, Denny L, Hanekom W, Soares A, Allan B, Williamson AL, Coetzee D, Olivier AJ, Burgers WA, Passmore JA. Immunology. 2009 Sep; 128(1 Suppl):e746-57. Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Wilkinson KA, Seldon R, Meintjes G, Rangaka MX, Hanekom WA, Maartens G, Wilkinson RJ. Am J Respir Crit Care Med. 2009;180(7):674-83. Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Black GF, Thiel BA, Ota MO, Parida SK, Adegbola R, Boom WH, Dockrell HM, Franken KL, Friggen AH, Hill PC, Klein MR, Lalor MK, Mayanja H, Schoolnik G, Stanley K, Weldingh K, Kaufmann SH, Walzl G, Ottenhoff TH; GCGH Biomarkers for TB Consortium. Clin Vaccine Immunol. 2009 Aug; 16(8):1203-12. Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth. Fletcher HA, Keyser A, Bowmaker M, Sayles PC, Kaplan G, Hussey G, Hill AV, Hanekom WA. BMC Med Genomics. 2009;2:10. 14. Comparison of T-SPOT.TB assay and tuberculin skin test for the evaluation of young children at high risk for tuberculosis in a community setting. Nicol MP, Davies MA, Wood K, Hatherill M, Workman L, Hawkridge A, Eley B, Wilkinson KA, Wilkinson RJ, Hanekom WA, Beatty D, Hussey G. Pediatrics. 2009;123(1):38-43.

PUBLICATION LIST 2008 (12)

Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. Scriba TJ, Kalsdorf B, Abrahams DA, Isaacs F, Hofmeister J, Black G, Hassan HY, Wilkinson RJ, Walzl G, Gelderbloem SJ, Mahomed H, Hussey GD, Hanekom WA. J Immunol. 2008;180(3):1962-70. Impact factor: 5.52 Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. Hawkridge A, Hatherill M, Little F, Goetz MA, Barker L, Mahomed H, Sadoff J, Hanekom W, Geiter L, Hussey G; South African BCG trial team. BMJ. 2008 Nov 13;337:a2052. Impact factor: 1.583 Are adolescents ready for tuberculosis vaccine trials? Mahomed H, Shea J, Kafaar F, Hawkridge T, Hanekom WA, Hussey GD. Vaccine. 2008;26(36):4725-30. Impact factor: 3.492 Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. Hanekom WA, Dockrell HM, Ottenhoff TH, Doherty TM, Fletcher H, McShane H, Weichold FF, Hoft DF, Parida SK, Fruth UJ. PLoS Med. 2008;5(7):e145. Impact factor: 3.73 Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.

MASTER PUBLICATION LIST

Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, Lang T, Veldsman A, Hatherill M, Merwe L, Fletcher HA, Mahomed H, Hill AV, Hanekom WA, Hussey GD, McShane H. J Infect Dis. 2008;198(4):544-52. Impact factor: 5.848 Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. Soares AP, Scriba TJ, Joseph S, Harbacheuski R, Murray RA, Gelderbloem SJ, Hawkridge A, Hussey GD, Maecker H, Kaplan G, Hanekom WA. J Immunol. 2008;180(5):3569-77. Impact factor: 5.52 Evaluation of the quality of informed consent in a vaccine field trial in a developing country setting. Minnies D, Hawkridge T, Hanekom W, Ehrlich R, London L, Hussey G. BMC Med Ethics. 2008 Sep 30; 9:15. Impact factor: 1.705 CD8+ T-cell interleukin-7 receptor alpha expression as a potential indicator of disease status in HIV-infected children. Sharma TS, Hughes J, Murillo A, Riley J, Soares A, Little F, Mitchell CD, Hanekom WA. PLoS One. 2008;3(12):e3986. Exposure of cord blood to Mycobacterium bovis BCG induces an innate response but not a T-cell cytokine response. Watkins ML, Semple PL, Abel B, Hanekom WA, Kaplan G, Ress SR. Clin Vaccine Immunol. 2008;15(11):1666-73. A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, Soler JH, Weichold F, Geiter L, Sadoff JC, Horwitz MA. J Infect Dis. 2008;198(10):1491-501. A comparison of IFNgamma detection methods used in tuberculosis vaccine trials. Beveridge NE, Fletcher HA, Hughes J, Pathan AA, Scriba TJ, Minassian A, Sander CR, Whelan KT, Dockrell HM, Hill AV, Hanekom WA, McShane H. Tuberculosis (Edinb). 2008;88(6):631-40. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. Ritz N, Hanekom WA, Robins-Browne R, Britton WJ, Curtis N. FEMS Microbiol Rev. 2008;32(5):821-41.

PUBLICATION LIST 2007 (5)

Immunological protection against tuberculosis. Hanekom WA, Abel B, Scriba TJ. S Afr Med J. 2007 Oct;97(10 Pt 2):973-7. Review. No abstract available. Impact factor: 1.702 Prospects for new tuberculosis vaccines. Hussey G. S Afr Med J. 2007 Oct;97(10 Pt 2):1001-2. No abstract available. Impact factor: 1.702 Tuberculosis contacts and prophylaxis. Hawkridge T. S Afr Med J. 2007 Oct;97(10 Pt 2):998-1000. No abstract available. Impact factor: 1.702 Childhood tuberculosis: old and new vaccines. Hussey G, Hawkridge T, Hanekom W.

MASTER PUBLICATION LIST

Paediatr Respir Rev. 2007 Jun;8(2):148-54. Epub 2007 Jun 4. Review. Impact factor: 2.792 Determining causes of mortality in children enrolled in a vaccine field trial in a rural area in the Western Cape Province of South Africa. Moyo S, Hawkridge T, Mahomed H, Workman L, Minnies D, Geiter LJ, Verver S, Kibel M, Hussey GD. J Paediatr Child Health. 2007 Mar;43(3):178-83. Impact factor: 1.254

PUBLICATION LIST 2006 (6)

Isolation of non-tuberculous mycobacteria in children investigated for pulmonary tuberculosis. Hatherill M, Hawkridge T, Whitelaw A, Tameris M, Mahomed H, Moyo S, Hanekom W, Hussey G. PLoS One. 2006 Dec 20; 1:e21. Impact factor: 3.73 The impact of a change in bacille Calmette-Guérin vaccine policy on tuberculosis incidence in children in Cape Town, South Africa. Mahomed H, Kibel M, Hawkridge T, Schaaf HS, Hanekom WA, Iloni K, Michaels D, Workman L, Verver S, Geiter L, Hussey GD. Pediatr Infect Dis J. 2006;25(12):1167-72. Impact factor: 3.569 Comparison of mantoux skin test with three generations of a whole blood IFN-gamma assay for tuberculosis infection. Mahomed H, Hughes EJ, Hawkridge T, Minnies D, Simon E, Little F, Hanekom WA, Geiter L, Hussey GD. Int J Tuberc Lung Dis. 2006 Mar;10(3):310-6. Erratum in: Int J Tuberc Lung Dis. 2006;10(6):708. Impact factor: 2.61 Bacillus Calmette Guerin vaccination of human newborns induces a specific, functional CD8+ T cell response. Murray RA, Mansoor N, Harbacheuski R, Soler J, Davids V, Soares A, Hawkridge A, Hussey GD, Maecker H, Kaplan G, Hanekom WA. J Immunol. 2006;177(8):5647-51. Impact factor: 5.52 Quantitative and functional differences between peripheral blood myeloid dendritic cells from patients with pleural and parenchymal lung tuberculosis. Mendelson M, Hanekom WA, Ntutela S, Vogt M, Steyn L, Maartens G, Kaplan G. Clin Vaccine Immunol. 2006;13(12):1299-306. The effect of bacille Calmette-Guérin vaccine strain and route of administration on induced immune responses in vaccinated infants. Davids V, Hanekom WA, Mansoor N, Gamieldien H, Gelderbloem SJ, Hawkridge A, Hussey GD, Hughes EJ, Soler J, Murray RA, Ress SR, Kaplan G. J Infect Dis. 2006;193(4):531-6.